AlloVir announces resignation of Chief Commercial Officer Jeroen van Beek effective Nov 23
Kalaris Therapeutics, Inc.
EVP and CCO Jeroen van Beek resigns Nov 23, 2022 to pursue new opportunities; will consult through Dec 31.
Company begins search for new head of Commercial organization.
Separation benefits: lump sum base salary through Dec 31, 2022, 2022 cash bonus, COBRA through Nov 23, 2023, and accelerated vesting of options/RSUs vesting by Dec 31, 2022.
Separation Agreement includes non-competition, confidentiality, and non-solicitation covenants.
On November 21, 2022, AlloVir, Inc. (“AlloVir” or the “Company”) announced that Jeroen van Beek, the Company’s Executive Vice President and Chief Commercial Officer, has resigned from the Company effective as of November 23, 2022 to pursue new opportunities.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Jeroen van Beek resigned as Executive Vice President and Chief Commercial Officer at Kalaris Therapeutics, Inc..
Action
resigned
Role
Executive Vice President and Chief Commercial Officer
Exact text from the filing
On November 21, 2022, AlloVir, Inc. (“AlloVir” or the “Company”) announced that Jeroen van Beek, the Company’s Executive Vice President and Chief Commercial Officer, has resigned from the Company effective as of November 23, 2022 to pursue new opportunities.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.